Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934099 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
A Phase 2 study, sponsored by LG Chem.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT03934099 is a Phase 2 study that has completed, run by LG Chem. The registered enrollment target is 156 participants.
The verdict
NCT03934099, a Phase 2 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
Interventions
- DRUG Placebo
- DRUG LC350189 formulated capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03934099
The ClinicalTrials.gov registry entry for NCT03934099 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03934099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03934099 about?
NCT03934099 is a clinical study titled "A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia". The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
What is the current status of trial NCT03934099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2019-12-02. Estimated completion is 2021-05-17.
What interventions are being tested in trial NCT03934099?
The interventions under investigation include: Placebo (DRUG), LC350189 formulated capsule (DRUG).
Who is sponsoring clinical trial NCT03934099?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.